EUVIMEDEUVIMED entdecken
Leserbrief

Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain

Shasha Hu, Dong Lyu, Jianjun Gao

Drug Discoveries & Therapeutics · 2025

DOI: 10.5582/ddt.2025.01010 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Drug Discoveries & Therapeutics, 2025. Verfasst von Shasha Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Acute Pain, NAV1.8 Voltage-Gated Sodium Channel, Voltage-Gated Sodium Channel Blockers. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opioids are commonly prescribed for the management of moderate to severe pain, but their use is associated with dependency and other adverse effects. For decades, the development of safe and effective non-addictive alternatives for treating moderate to severe pain has seen limited progress. On January 30, 2025, the U.S. Food and Drug Administration approved suzetrigine, the first Nav1.8 inhibitor, for the treatment of moderate to severe acute pain. Nav1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral nociceptive neurons, which are responsible for transmitting pain signals. By highly selectively inhibiting the Nav1.8 channel, suzetrigine can effectively alleviate pain. Unlike opioids, this drug does not induce euphoria or excitement in the brain, thereby eliminating concerns about addiction. Suzetrigine offers a novel therapeutic option and a potential combination for multimodal analgesia, with the promise of transforming acute pain management and establishing new treatment standards.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute PainNAV1.8 Voltage-Gated Sodium ChannelVoltage-Gated Sodium Channel BlockersAnimalsHumansDrug ApprovalUnited States

Stichwörter der Autor:innen

Nav1.8Opioidspainpainful diabetic peripheral neuropathy (DPN)painful lumbosacral radiculopathy (LSR)postoperative

Substanzen

NAV1.8 Voltage-Gated Sodium ChannelSCN10A protein, humanVoltage-Gated Sodium Channel Blockers

Autor:innen und Institutionen

  • Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Department of Burn and Plastic Surgery, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.
  • Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.

Zitieren

APA

Hu, S., Lyu, D., & Gao, J. (2025). Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2025.01010

Vancouver

Hu S, Lyu D, Gao J. Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain. Drug Discoveries & Therapeutics. 2025. doi:10.5582/ddt.2025.01010

BibTeX
@article{Hu2025,
  author = {Hu, Shasha and Lyu, Dong and Gao, Jianjun},
  title = {Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain},
  journal = {Drug Discoveries & Therapeutics},
  year = {2025},
  doi = {10.5582/ddt.2025.01010}
}
Kostenlos starten →